Advances in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".
Deadline for manuscript submissions: 25 March 2025 | Viewed by 32
Special Issue Editors
Interests: hypertrophic cardiomyopathy; coronary flow reserve; coronary physiology; echocardiography
Special Issues, Collections and Topics in MDPI journals
Interests: hypertrophic cardiomyopathy; stress echocardiography; coronary physiology; echocardiography
2. Research Centre (CSELS), Institute for Health and Wellbeing, Faculty of Health and Life Sciences, Coventry University, Coventry CV1 5FB, UK
Interests: heart failure–risk stratification, diagnostics and management; lifestyle medicine; hypertrophic cardiomyopathy; AI in cardiovascular medicine
Special Issue Information
Dear Colleagues,
Hypertrophic cardiomyopathy is the most common inherited cardiac disease which is associated with increased cardiovascular morbidity and mortality. As a result of heterogeneous clinical courses and phenotypes of hypertrophic cardiomyopathy, risk stratification remains challenging and is mainly focused on sudden cardiac death. However, certain echocardiographic, cardiac magnetic resonance imaging and clinical parameters used for sudden cardiac death prediction have limited prognostic value in predicting other hypertrophic cardiomyopathy-related cardiovascular events, such as the progressive deterioration of the left ventricular systolic function with heart failure development or an ischemic stroke. Advances in diagnostics and treatment have significantly improved the outcome and quality of life of HCM patients. With continued research and innovation, the future holds promise for even more effective management and potential therapy for this challenging condition.
This Special Issue aims to identify the gaps in the diagnosis and treatment of HCM based on a combination of original research and review papers.
The potential topics include the following:
Advances in Diagnostics
- Genetic testing;
- Advanced imaging techniques;
- Biomarkers.
Advances in Treatment
- Pharmacological therapies;
- Surgical and interventional procedures;
- Lifestyle and exercise;
- Gene therapy.
Dr. Milorad Tesic
Dr. Vojislav Giga
Prof. Dr. Djordje G. Jakovljević
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hypertrophic cardiomyopathy
- left ventricular hypertrophy
- diagnosis
- multimodality imaging
- genetics
- treatment
- risk stratification
- outcome
- biomarkers
